whatshot

PHMMF   $38.526714  -43.46% Market Closed

PHARMA MAR SA NEW
show_chart Advanced Chart of PHMMF
Last Events:

2023-03-29 Signal in Stochastic changed from bullish reversal to bullish. The stochastic indicator is in the upper part of the neutral territory and it grows. These factors indicate that positive dynamics persists. Last signal: up-crossing the middle level.

2023-03-29 Signal in RSI changed from bearish weakening to bearish recovery. RSI indicator is in the lower part of the neutral territory and it heading south. These factors indicate that negative dynamics is recovering. Last signal: exit from the overbought zone.

2023-03-29 Signal in EMA20 changed from bearish reversal to n/a. 2022-12-12 the price crossed up the moving average line and getting closer to the MA, which means that the short-term upside trend weakens.

2023-03-29 Trend Power changed from to medium strength.

2023-03-29 Signal in Stochastic changed from bullish to bullish reversal. The stochastic indicator is in the lower part of the neutral territory and left the oversold territory. These factors indicate that perhaps the downside trend is coming to an end price will probably head north Last signal: main and signal line crossing.

2023-03-29 Signal in RSI changed from bearish recovery to bearish weakening. RSI indicator is in the lower part of the neutral territory and it heading north. These factors indicate that the upside trend is forming Last signal: entrance to the overbought zone.

2023-03-29 Signal in EMA20 changed from n/a to bearish reversal. 2022-08-02 the price crossed down the moving average line and getting closer to the MA, which means that the short-term downside trend weakens.

2023-03-29 Trend Power changed from medium strength to .

Current temperature: 0.00
ST: 0, Cor:

Analyst Recommendations:
Number of estimates 11
Target Price Mean 113.73
Mean unverified/preliminary 113.73 / 113.73
Target Price Low / High 70.17 / 139.98
Median / STD DEV 111.98 / 18.04
Tech Forecasts:
More signals
  < 1M 1-3M > 3M
total Sell Sell -
rsi Sell - -
macd - - -
stoch Sell Sell -
ma20 - - -
ma50 Sell - -
ma100 - - -
Candlestick PatternFeb. 22, 2022 Doji - is formed when the open and the close are the same or very close. The body of candle is small. The length of the shadows are not important. The appearance of a Doji should alert the investor of major indecision.
ISIN ES0169501022
ceo Mr. Jose Maria Fernandez Sousa-Faro Ph.D.
Website https://www.pharmamar.com
Pharma Mar, S.A., a biopharmaceutical company, engages in the research, development, production, and commercialization of bio-active principles for the use in oncology in Spain, Italy, Germany, Ireland, France, rest of the European Union, the United States, and internationally. The company operates through Oncology and RNA Interference segments. It develops and commercializes Yondelis for the treatment of soft tissue sarcoma and for ovarian cancer; Aplidin for treating R/R multiple myeloma; and Zepzelca to treat patients with small cell lung cancer. The company develops Ecubectedin (PM14), which is in phase II clinical trials for the treatment of solid tumors, as well as in Phase I clinical trials for the treatment of soft tissue sarcoma and prostate cancer; PM534 that is Phase I clinical trials for treating solid tumors; PM54, which is in Phase I clinical trials for the treatment of solid tumors; SYL1801 that is in phase II clinical trials for treating macular degeneration; SYL116011, which is in preclinical studies for the treatment of ocular allergies; and SYL A and B that is in investigational studies to treat retinitis pigmentosa. In addition, it engages in the research, development, production, and sale of products with therapeutic activity based on reducing or silencing gene expression. Pharma Mar, S.A. was incorporated in 1986 and is based in Madrid, Spain.